Showing 2871-2880 of 4063 results for "".
- REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trialshttps://modernod.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/REGENXBIO Inc. announced financial results for the quarter ended June 30, 2018, and recent operational highlights including updates to interim data from its ongoing clinical trials. Financial Results Cash, cash equivalents, and marketable securities were $306.3 million as of June
- Data from BioTime’s OpRegen Program to Be Presented at AAO 2018https://modernod.com/news/data-from-biotimes-opregen-program-to-be-presented-at-aao-2018/2479983/BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30
- The Foundation Fighting Blindness Presents the Emerging Science Showcase at OIS Retina 2018https://modernod.com/news/the-foundation-fighting-blindness-presents-the-emerging-science-showcase-at-ois-retina-2018/2480012/The Foundation Fighting Blindness (FFB) Emerging Science Showcase will lead off the upcoming Ophthalmology Innovation Summit for Retina, held July 20, 2018, in Vancouver, B.C., Canada. Moderated by FFB COO Jaso
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi
- Lightmed Announces New Office Location in Caesarea, Israelhttps://modernod.com/news/lightmed-announces-new-office-location-in-caesarea-israel/2480027/Lightmed announced it has opened a new office location in Caesarea, Israel to expand its business and technological investments, and leverage Israel’s diverse and experienced medical technology talent pool. “Th
- Association of Optometrists and SECO International Announce Partnership with Armed Forces Optometric Society for Therapeutics London 2018https://modernod.com/news/association-of-optometrists-and-seco-international-announce-partnership-with-armed-forces-optometric-society-for-therapeutics-london-2018/2480047/The Association of Optometrists (AOP) and SECO International have partnered with the Armed Forces Optometric Society (AFOS) to present “Therapeutics London 2018,” an optometric continuing education and training (CET) conference focusing on therapeutics, being held September 23-24, 201
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Market Scope: OCT Market to Generate $632 Million in Revenues in 2018https://modernod.com/news/market-scope-oct-market-to-generate-632-million-in-revenues-in-2018/2480062/Market Scope estimates that the optical coherence tomography (OCT) market will generate $632 million in total manufacturer revenues in 2018, and the market will grow to $797 million by 2023 at a compound annual growth rate of 4.8 percent. Market Scope expects much of this growth to come fr
- Glaukos Announces FDA Approval for the iStent inject Trabecular Micro-Bypass Systemhttps://modernod.com/news/glaukos-announces-fda-approval-for-the-istent-inject-trabecular-micro-bypass-system/2480073/Glaukos announced it has received premarket approval from the FDA for the »iStent inject Trabecular Micro-Bypass System, which is indicated for the reduction of IOP in adult
- ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DChttps://modernod.com/news/thrombogenics-partners-with-prevent-blindness-at-2018-focus-on-eye-health-national-summit-in-washington-dc/2480077/ThromboGenics announced its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit which takes place on July 18, 2018, at the National Press Club in Washington, DC. The Focus on Eye Health National Summit aims to facilitate dialogue around vi